Skip to main content


Volume 10 Supplement 1

Co-stimulation blockade: from bench to bedside


Edited by Jörg J Goronzy

Publication of this supplement has been sponsored by Bristol-Myers Squibb Company

  1. Content type: Review

    Over the past decade and a half, advances in our understanding of the pathogenesis of immune-mediated diseases such as rheumatoid arthritis (RA) have translated directly into benefit for patients. Much of this...

    Authors: Andrew P Cope

    Citation: Arthritis Research & Therapy 2008 10(Suppl 1):S1

    Published on:

  2. Content type: Review

    T-cell activation and differentiation depend on the signal strength received by the T-cell receptor and on signals provided by co-stimulatory molecules. The most prominent co-stimulatory molecule is CD28, whic...

    Authors: Jörg J Goronzy and Cornelia M Weyand

    Citation: Arthritis Research & Therapy 2008 10(Suppl 1):S3

    Published on:

  3. Content type: Review

    Currently available information from clinical trials and open-label extensions suggest that abatacept is a good alternative to other biologicals in rheumatoid arthritis. Although at first glance the efficacy o...

    Authors: Rene Westhovens and Patrick Verschueren

    Citation: Arthritis Research & Therapy 2008 10(Suppl 1):S4

    Published on:

  4. Content type: Review

    T-cell biology has regained importance in the pathogenesis of rheumatoid arthritis. Despite the significant improvements associated with the introduction of tumor necrosis factor-α blockade, reasonable proport...

    Authors: Maya H Buch, Edward M Vital and Paul Emery

    Citation: Arthritis Research & Therapy 2008 10(Suppl 1):S5

    Published on:

Annual Journal Metrics